We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-18.72%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$161M
AUM Growth
-$49.3M
Cap. Flow
-$8.81M
Cap. Flow %
-5.46%
Top 10 Hldgs %
56.91%
Holding
57
New
6
Increased
7
Reduced
18
Closed
12

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$8.65M
2
GILD icon
Gilead Sciences
GILD
+$8.6M
3
BIIB icon
Biogen
BIIB
+$5.49M
4
AMGN icon
Amgen
AMGN
+$4.68M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.21M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$11.7M
2
ILMN icon
Illumina
ILMN
+$5.73M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$5.67M
4
AERI
Aerie Pharmaceuticals
AERI
+$5.17M
5
PBYI icon
Puma Biotechnology
PBYI
+$5.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
26
Ionis Pharmaceuticals
IONS
$10.4B
$1.7M 1.05%
40,000
-11,500
-22% -$587K
NKTR icon
27
Nektar Therapeutics
NKTR
$2.55B
$1.55M 0.96%
+4,000
New +$2.41M
SRPT icon
28
Sarepta Therapeutics
SRPT
$2.28B
$1.46M 0.9%
17,000
-10,000
-37% -$1.25M
BLUE
29
DELISTED
bluebird bio
BLUE
$1.32M 0.82%
1,312
– –
AGIO icon
30
Agios Pharmaceuticals
AGIO
$2.05B
$1.32M 0.82%
36,500
– –
SAGE
31
DELISTED
Sage Therapeutics
SAGE
$1.2M 0.75%
15,996
– –
HZNP
32
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.06M 0.66%
69,000
– –
STRO icon
33
Sutro Biopharma
STRO
$353M
$1.05M 0.65%
14,665
– –
AMRN
34
Amarin Corp
AMRN
$297M
$854K 0.53%
+4,000
New +$1.46M
GMED icon
35
Globus Medical
GMED
$11.1B
$822K 0.51%
24,200
-4,800
-17% -$239K
ARRY
36
DELISTED
Array Biopharma Inc
ARRY
$811K 0.5%
72,500
-772,000
-91% -$11.7M
GWPH
37
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$732K 0.45%
9,600
– –
KYNB
38
Kyntra Bio
KYNB
$32.4M
$716K 0.44%
788
-468
-37% -$526K
FSTX
39
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$596K 0.37%
18,250
– –
SUPN icon
40
Supernus Pharmaceuticals
SUPN
$2.57B
$547K 0.34%
20,953
– –
FOLD
41
DELISTED
Amicus Therapeutics
FOLD
$440K 0.27%
58,600
– –
SGMO
42
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$432K 0.27%
48,000
-65,000
-58% -$807K
AERI
43
DELISTED
Aerie Pharmaceuticals
AERI
$425K 0.26%
15,000
-110,179
-88% -$5.17M
ONCE
44
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$369K 0.23%
12,000
– –
PTLA
45
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$367K 0.23%
+24,000
New +$494K
CRVS icon
46
Corvus Pharmaceuticals
CRVS
$1.24B
– –
-108,000
Closed -$710K
JAZZ icon
47
Jazz Pharmaceuticals
JAZZ
$16.3B
– –
-21,600
Closed -$2.79M
MDGL icon
48
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-10,000
Closed -$1.64M
MRUS
49
DELISTED
Merus
MRUS
– –
-75,060
Closed -$1.14M
PBYI icon
50
Puma Biotechnology
PBYI
$477M
– –
-144,300
Closed -$5.07M
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2018 Portfolio in Review

As of Q4 2018, International Biotechnology Trust held 57 positions worth $161M, down 23% from $210M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

International Biotechnology Trust withdrew a net $8.81M in Q4 2018, closing 12 positions and reducing 18 holdings. Its most notable exit was Adamas Pharmaceuticals, an estimated $5.67M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Biogen worth $4.06M.

  • International Biotechnology Trust's largest Q4 2018 buy was Biogen: 17,200 shares worth $4.06M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q4 2018, an estimated $8.65M increase.
  • International Biotechnology Trust's biggest Q4 2018 reduction was Array Biopharma Inc, cutting an estimated $11.7M.
  • International Biotechnology Trust fully exited Adamas Pharmaceuticals in Q4 2018, selling an estimated $5.67M.
  • International Biotechnology Trust's ten largest holdings make up 57% of its $161M portfolio in Q4 2018.
  • International Biotechnology Trust opened 6 new positions and closed 12 in Q4 2018.
  • International Biotechnology Trust's portfolio value fell 23% quarter-over-quarter to $161M.

Based on International Biotechnology Trust's 13F filing for Q4 2018, filed 14 Feb 2019.